Book Value per Share: Denali Therapeutics Inc. (DNLI)

Denali Therapeutics (DNLI) - corporate logo

This daily price chart for Denali Therapeutics (DNLI) illustrates the current trend, where the key indicator is fixed at 5.27. Drug development is slowing due to geopolitical strife and restrictions on the cross-border exchange of biodata. Meanwhile, Denali Therapeutics relies on a team of elite scientists and a progressive incentive system, while the massive unmet demand for neurodegeneration treatment, combined with alliances with pharma behemoths, opens up colossal sales prospects.

Denali (DNLI) Equity per Share: for the period 07/04/2022 - 10/28/2026

denalitherapeutics.com - analytical breakdowns and key metrics (DNLI)

- price and consensus price forecast:
Price Chart Denali Therapeutics Inc|DNLI - Price Target Chart
- market capitalization data:
Market Capitalization Denali Therapeutics Inc.|DNLI - Company Buyout Price
- book capitalization data:
Net Assets per Single Share Denali Therapeutics|DNLI - Accounting Capitalization|Market Capitalization to Book Value Ratio denalitherapeutics.com|DNLI - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Denali Therapeutics|DNLI - Long-Term Debt to Capital|Short-Term Debt to Equity Denali Therapeutics Inc.|DNLI - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Denali Therapeutics Inc.
Fundamental company valuation:Denali Therapeutics Inc, DNLI
Manufactured products of Denali Therapeutics Inc.

The development of blood-brain barrier crossing technologies at Denali Therapeutics (DNLI) requires significant capital expenditures in the absence of current sales. The bps_co metric measures the residual value of net assets available to each shareholder after all liabilities are settled. This metric determines the intrinsic value of the business, excluding market noise and speculative expectations. This trend captures the burn rate of R&D resources. By analyzing the equity per common share chart, an investor can see the company's actual asset foundation.

Competitors of Denali Therapeutics (DNLI)

BIIB - Net Assets per Single Share|NBIX - Net Assets per Single Share|Regencell Bioscience - Book Value per Share|AXSM (axsome.com) - Net Assets per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|harmonybiosciences.com - Book Value per Share|Net Assets per Single Share Biohaven (BHVN)|AMLX: Accounting Value of a Share|Net Assets per Single Share TRVI|Praxis Corp (PRAX) - Net Asset Value per Share|Book Value per Share Anavex Life Sciences (AVXL)|Equity per Share ceribell.com|Prothena Biosciences - Book Value per Share|Net Asset Value per Share ALEC (alector.com)|ANNX - Net Assets per Single Share|Equity per Share Omeros Corp OMER|Neurogene Inc. - Book Value per Share|ACIU: Book Value per Share|Voyager Therapeutics, Inc. (VYGR) - Net Assets per Single Share|Neumora (NMRA) - Net Assets per Single Share|SCLX: Book Value per Share|Net Assets per Share Tevogen Bio Inc. (TVGN)|Alpha Cognition (ACOG) - Accounting Value per Share|Accounting Value of a Share Cognition Therapeutics Inc. CGTX|Accounting Value per Share Inhibikase Therapeutics, Inc. (IKT)|Book Price of a Share Cassava Sciences Inc SAVA|Book Value per Share Assertio Therapeutics (ASRT)|COYA - Accounting Value of a Share|Book Value per Share VTGN|OVID (Ovid Therapeutics) - Net Asset Value per Share|ABOS - Net Assets per Single Share|Accounting Value of a Share CervoMed, Inc.|Book Value per Share ATHE|Book Value per Share CLNN (clene.com)|PepGen (PEPG) - Net Assets per Single Share|Share Book Value Jupiter Neurosciences, Inc. JUNS|RLMD (Relmada Therapeutics, Inc.) - Book Value per Share|Annovis Bio Inc (ANVS) - Net Asset Value per Share|GRCE: Accounting Value per Share|Book Value per Share Firefly Neuro|ANEW Medical (KLTO) - Accounting Value per Share|Book Price of a Share NeuroSense Therapeutics, Ltd.|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - Book Value per Share|Net Assets per Share metaviatx.com (MTVA)|NeurAxis, Inc - Book Value per Share|Helius Medical Technologies, Inc. - Accounting Value per Share|Net Assets per Single Share PASG (Passage Bio Corp)|NEUP - Net Assets per Share|Book Value per Share Minerva Neurosciences, Inc.|ATHA (Athira Pharma Inc) - Equity per Share|Net Assets per Single Share Addex Therapeutics, Ltd. (ADXN)|Equity per Share ALZN|Net Assets per Single Share Cyclerion Therapeutics (CYCN)|Net Assets per Single Share protagenic.com (PTIX)|Book Value per Share KTTA|Cortigent Inc - Net Assets per Share|Avenue Therapeutics, Inc (ATXI) - Net Assets per Single Share|BCLI - Equity per Share|Book Value per Share CARA|Net Asset Value per Share chromocell.com|ELYM (Eliem Therapeutics, Inc.) - Accounting Value per Share|Book Value per Share ITCI|Longboard Pharma (LBPH) - Net Assets per Single Share|Accounting Value of a Share MRNS (Marinus Pharma)|NKGN: Net Assets per Single Share|Net Asset Value per Share neurobopharma.com NRBO|Sage Therapeutics (SAGE) - Book Value per Share|SNPX - Equity per Share|Book Value per Share TRVN|VIGL (Vigil Neuroscience, Inc.) - Net Asset Value per Share|Net Assets per Single Share Anew Medical (WENA)|Equity per Share cerevel.com